title: Retrospective analysis of 105 cases with uterine sarcoma.
abstract: To evaluate the role of adjuvant therapy in survival and to identify important prognostic factors in uterine sarcoma. One hundred five patients with uterine sarcoma have been retrospectively researched to evaluate the results in this tumor group. 43.8% had leiomyosarcoma, 28.6% had endometrial stromal sarcoma and 27.6% had a malign Mullarian mixed tumor while the distribution according to the histological subgroups were found to be 42.6,16.2 and 41.2% in grade I, II and III tumors respectively. 38.1% of the patients had Radiotherapy, 18.1% had chemotherapy and 12.4% had chemoradiotherapy in addition to surgery. The distant metastases rate is 30% and the local recurrence is 16.2%. All the local recurrences and 90% of the distant metastases have occurred within the first two years. The disease free survival and overall survival rates at 3rd and 5th years are 54.46, 49.88, 54.63 and 51.09% all respectively. In our series, univariate analysis for overall survival demonstrated statistical significance for radical surgery, grade, stage, age, menopausal status and presence of RT in treatment modality, but; histology, number of mitosis, tumor size demonstrated no significance. Our data favors treatment for uterine sarcoma with radical surgery plus radiotherapy alone over 54 Gy or with chemotherapy.
authors.affiliation: Okmeydani Training and Research Hospital, Department of Radiation Oncology, 8 Cadde Inci 3 daire 8, Atasehir-Kadikoy, 34578 Istanbul, Turkey. adnan@yoney.net
authors.forename: Adnan
authors.initials: A
authors.lastname: Yoney
authors.forename: Bekir
authors.initials: B
authors.lastname: Eren
authors.forename: Sukran
authors.initials: S
authors.lastname: Eskici
authors.forename: Adile
authors.initials: A
authors.lastname: Salman
authors.forename: Mustafa
authors.initials: M
authors.lastname: Unsal
mesh_terms: D018195:Adenosarcoma / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D001859:Bone Neoplasms / Q000556:secondary; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D018203:Sarcoma, Endometrial Stromal / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy